Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

L Yu, J Wei, P Liu - Seminars in cancer biology, 2022 - Elsevier
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

M Tufail, JJ Hu, J Liang, CY He, WD Wan… - Journal of translational …, 2024 - Springer
Breast cancer (BC) is a multifaceted disease characterized by distinct molecular subtypes
and varying responses to treatment. In BC, the phosphatidylinositol 3-kinase (PI3K) pathway …

Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements

S Akter, MA Rahman, MN Hasan, H Akhter, P Noor… - Cells, 2022 - mdpi.com
Aggressive and recurrent gynecological cancers are associated with worse prognosis and a
lack of effective therapeutic response. Ovarian cancer (OC) patients are often diagnosed in …

Survivin (BIRC5): Implications in cancer therapy

G Siragusa, L Tomasello, C Giordano, G Pizzolanti - Life Sciences, 2024 - Elsevier
Abstract Inhibitors of Apoptosis proteins (IAPs) were discovered through experiments aimed
at rescuing apoptosis in insects. Classically associated with the inhibition of apoptosis, the …

[HTML][HTML] The role of bcl-2 and beclin-1 complex in “switching” between apoptosis and autophagy in human glioma cells upon LY294002 and sorafenib treatment

A Zając, A Maciejczyk, J Sumorek-Wiadro, K Filipek… - Cells, 2023 - mdpi.com
Background: Gliomas are the most malignant tumors of the central nervous system. One of
the factors in their high drug resistance is avoiding programmed death (PCD) induction. This …

Multiple molecular mechanisms to overcome multidrug resistance in cancer by natural secondary metabolites

MZ El-Readi, AM Al-Abd, MA Althubiti… - Frontiers in …, 2021 - frontiersin.org
Plant secondary metabolites (SMs) common natural occurrences and the significantly lower
toxicities of many SM have led to the approaching development and use of these …

Doxorubicin-sanguinarine nanoparticles: formulation and evaluation of breast cancer cell apoptosis and cell cycle

MZ El-Readi, MA Abdulkarim… - Drug Development …, 2024 - Taylor & Francis
Background Therapeutic resistance fails cancer treatment. Drug-nanoparticle combinations
overcome resistance. Sanguinarine-conjugated nanoparticles may boost sanguinarine's …

Tamoxifen and oxidative stress: an overlooked connection

NS Ahmed, M Samec, A Liskova, P Kubatka, L Saso - Discover Oncology, 2021 - Springer
Tamoxifen is the gold standard drug for the treatment of breast cancer in pre and post-
menopausal women. Its journey from a failing contraceptive to a blockbuster is an example …

[HTML][HTML] Involvement of PI3K pathway in glioma cell resistance to temozolomide treatment

A Zając, J Sumorek-Wiadro, E Langner, I Wertel… - International Journal of …, 2021 - mdpi.com
The aim of the study was to investigate the anticancer potential of LY294002 (PI3K inhibitor)
and temozolomide using glioblastoma multiforme (T98G) and anaplastic astrocytoma …

Significance of targeting VEGFR-2 and cyclin D1 in luminal-A breast cancer

A N. Abdalla, A Qattan, W H. Malki, I Shahid… - Molecules, 2020 - mdpi.com
The hormonal luminal-A is the most pre-dominant sub type of breast cancer (BC), and it is
associated with a high level of cyclin D1 in Saudi patients. Tamoxifen is the golden therapy …